Hikma Pharmaceuticals signs deal with Theravance for Vibativ
1st Jul 2013 09:04
Hikma Pharmaceuticals has signed an exclusive commercialisation agreement with Theravance for Vibativ in the Middle East and North Africa (MENA). Vibativ is a bactericidal, once-daily antibiotic for bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a dang
Read moreMonday broker round-up UPDATE
17th Jun 2013 07:21
Antofagasta: UBS reduces target price from 1140p to 1050p, while upgrading from neutral to buy. ARM Holdings: Analysts at Numis have cut their view on the shares to reduce from hold. Associated British Foods: Nomura cuts target price from 1800p to 1650p downgrading to reduce. Atkins: Jefferies u
Read moreHikma Pharmaceuticals shrinks stake
24th May 2013 15:36
Said Darwazah, the Chief Executive Officer of Hikma Pharmaceuticals, has reduced his stake in the FTSE 250 company, it was announced after Thursday's close. The director, who was the Minister of Health for the Hashemite Kingdom of Jordan from 2003 to 2006, sold 188,445 shares over a period of six d
Read moreWednesday broker round-up UPDATE
22nd May 2013 09:37
Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation. Amara Mining: Westhouse Securities cuts target price from 110p to 90p retaining a buy recommendation. Amlin: Westhouse Securities moves target price from 455p to 470p and upgrades to add.
Read moreHikma Pharmaceuticals non-exec sells 5,700 shares
21st May 2013 15:52
Ronald Goode, a non-Executive Director of Hikma Pharmaceuticals, has disposed of 5,700 shares at 983.00p each. The £56,031 sale comes less than a week after the company upgraded its 2013 revenue growth forecast following a strong start to the year. In an announcment released May 16th, the group t
Read moreHikma Pharmaceuticals upgrades 2013 revenue outlook
16th May 2013 12:23
Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year". The group expects revenue to rise 13% this year, up from its previous guidance of 10%, driven by the performance of Branded and Injectables and Generics
Read moreLondon close: Stocks hit by fears over growth, US earnings
17th Apr 2013 16:50
Fears over economic growth and a raft of disappointing earnings in the States weighed heavily on global markets on Wednesday, while a number of heavyweight stocks going ex-dividend dampened the FTSE 100 in London. Bank of America (BofA) was the first major US bank to miss forecasts this earnings se
Read moreFTSE 250 movers: Hikma Pharmaceuticals hit by target price cut
17th Apr 2013 15:19
Hikma Pharmaceuticals was a heavy faller today after going ex-dividend and being hit by a target price cut from Jefferies, from 1,150p to 1,040p. The cut came after the group announced its plan to hold on to its global injectables business. Miners were under the weather as investors looked to inves
Read moreLondon midday: FTSE 100 on track for fourth straight loss
17th Apr 2013 11:39
A number of heavyweight stocks going ex-dividend assured that London's FTSE 100 index was in the red for a fourth consecutive day on Wednesday, while concerns over the global economy continued to weigh on sentiment. Global growth fears have hit markets over the last few days after a surprise slowdo
Read moreBroker tips: Tesco, Burberry, Hikma
17th Apr 2013 11:24
Panmure Gordon has maintained its 'buy' rating and 440p target price for supermarket group Tesco, highlighting a 'welcome shift in strategy' following the firm's full-year results. Panmure reckons that Tesco is on track in the UK and expects the recovery to "slowly emerge" this year and said that i
Read moreBroker snap: Jefferies cuts target for Hikma but stays upbeat
17th Apr 2013 11:16
Jefferies has cut its price target for pharmaceuticals firm Hikma from 1,150p to 1,040p after the company's decision to hold on to its global injectables business. Hikma said on Wednesday that it has seen a "significant amount of interest" in the injectables business by third parties. However, the
Read moreHikma Pharmaceuticals decides not to sell Injectables business
17th Apr 2013 08:37
FTSE 250-listed company Hikma Pharmaceuticals has announced that following the conclusion of its strategic review of its global Injectables business, it has decided that the business should remain part of the Hikma Group. The reason behind the decision is that it sees the business as holding a uni
Read moreWednesday broker round-up UPDATE
17th Apr 2013 07:20
African Barrick Gold: Deutsche Bank cuts target price from 230p to 173p, while its hold recommendation is reiterated. Ashmore Group: Morgan Stanley raises target price from 395p to 444p and maintains an equal-weight rating. Ashtead Group: Jefferies increases target price from 615p to 690o and reit
Read moreThursday broker round-up UPDATE
14th Mar 2013 07:11
Amara Mining: After having been under review, Cantor Fitzgerald reinitiates coverage with a price target of 81p and a buy recommendation. Antofagasta: Citigroup shifts target price from 990p to 1000p, but retains its sell recommendation. Ashtead Group: Investec raises target price from 475p to 700
Read moreLondon open: Ex-div stocks weigh on FTSE 100 early on
13th Mar 2013 08:33
Traders chose to take profits on Wednesday morning, taking advantage of the strong gains seen in previous sessions, with the FTSE 100 pulling back sharply from five-year highs. So far this year, the index has gained nearly 10% and is trading near levels not seen since late 2007. According to Reute
Read more